Nanoform Finland Oyj (NANOFH.HE)

1.6500 -0.0450 (-2.65%) At close: 06:16PM EET

Nanoform Finland Oyj

Cultivator II
Viikinkaari 4
Helsinki 00790
Finland
358 2937 00150
https://www.nanoform.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 165

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Albert Alexander Haeggstrom	CFO & Director	79.24k	N/A	1971
Prof. Edward Olof Haeggstrom	Co-Founder & CEO	N/A	N/A	1969
Mr. Henri von Haartman	Director of Investor Relations	N/A	N/A	N/A
Mr. Peter Hanninen	General Counsel	N/A	N/A	1988
Dr. David Rowe	Head of Manufacturing	N/A	N/A	1967
Mr. Christian Jones	Chief Commercial Officer	N/A	N/A	1980
Mr. Antonio Da Silva	Chief of Business Operations	N/A	N/A	1974
Ms. Johanna Kause	Chief Quality Officer	N/A	N/A	1971

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Nanoform Finland Oyj provides nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.

Corporate Governance

Nanoform Finland Oyj’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.